Acquisition leverage Evergreen Theragnostics was acquired by Lantheus in 2025 for 250M, signaling strong strategic fit and potential cross-sell opportunities for radiopharmaceuticals, CDMO services, and regulatory support within Lantheus' expanding portfolio.

Clinical collaboration Active and upcoming clinical development programs in radioligand therapies for small cell lung cancer, plus ongoing licensing deals with Medical University of Innsbruck, suggest opportunities to position complementary radiopharma capabilities and accelerate joint development efforts.

Scale and reach Smaller, focused CDMO with 51-200 employees and a revenue baseline in the low millions presents a buying or partnership target for larger players seeking to augment manufacturing capacity, regulatory affairs, and process development in radiopharmaceuticals.

Strategic partnerships Past collaborations with Jubilant Radiopharma and licensing/licensing-style agreements indicate openness to co-development, kit-based production, and distribution arrangements, enabling BD teams to propose integrated supply and commercialization deals.

Financial health signal Recent capital raises totaling about 60M and a notable 26M funding round, along with a major acquisition, reflect investor confidence and potential for scalable manufacturing programs, making Evergreen an attractive partner for customers needing robust, compliant production pipelines.